We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
IQV has an impressive earnings surprise history, having surpassed the Zacks Consensus Estimate in the trailing four quarters, the average surprise being 1.8%.
IQVIA’s Q3 Expectations
The Zacks Consensus Estimate for revenues is pegged at $3.9 billion, implying 3.1% growth from the year-ago quarter’s actual. The top line is likely to have been driven by increased revenues across the Technology and Analytics segment (TAS), and Research and Development segments (RD&S).
Our estimate for revenues from TAS is pegged at $1.5 billion, suggesting a 4.9% gain on a year-over-year basis. This segment’s revenue growth is expected to be fueled by improvements in Consulting and Analytics. The launch of a GenAI solution, which collects structured and unstructured survey inputs from more than 30,000 healthcare professionals across 36 countries in multiple languages and delivers analytics and insights to its clients, is likely to have benefited this segment.
The RD&S revenues are expected to be $2.2 billion, hinting at a 2.4% rise from the year-ago reported figure.Revenues in this segment are anticipated to be driven by the strength across VRSK’s oncology department.
Our estimate for Contract sales and Medical solutions’ (CSMS) revenues is pegged at $182.9 million, implying a marginal decline from the year-ago quarter’s actual.
The consensus estimate for earnings per share is pegged at $2.8, suggesting 12.9% year-over-year growth. The bottom line is expected to have been driven by revenue growth and cost management discipline.
Our estimate for the third quarter’s adjusted EBITDA is pegged at $938.6 million, suggesting 5.7% year-over-year growth.
What Our Model Says About IQV
Our proven model does not conclusively predict an earnings beat for IQVIA this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here. You can uncover the best stocks before they are reported with our Earnings ESP Filter.
IQV has an Earnings ESP of -0.54% and a Zacks Rank of 3 at present.
Stocks to Consider
Here are a few stocks from the broader Business Services sector, which, according to our model, have the right combination of elements to beat on earnings this time around.
Mastercard (MA - Free Report) : The Zacks Consensus Estimate for the company’s third-quarter 2024 revenues is pegged at $7.3 billion, suggesting growth of 11% from the year-ago quarter. For earnings, the consensus mark is pegged at $3.7 per share, indicating a 10% year-over-year rise. MA beat the consensus estimate in the past four quarters. It has an earnings surprise of 3.5%, on average.
MA has an Earnings ESP of +0.44% and a Zacks Rank of 2 at present. It is scheduled to declare its third-quarter 2024 results on Oct. 30.
Visa (V - Free Report) : The Zacks Consensus Estimate for third-quarter 2024 revenues is pegged at $9.5 billion, indicating an increase of 10.2% from the year-ago quarter’s actual. For earnings, the consensus mark is pegged at $2.6 per share, indicating a 10.7% increase from the year-ago quarter’s actual. V beat the consensus estimate in the past four quarters, the earnings surprise being 2.9%, on average.
V has an Earnings ESP of +0.05% and a Zacks Rank of 3 at present. It is scheduled to declare its third-quarter 2024 results on Oct. 29.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report predicting the 7 stocks that will soar highest in the coming month.
Image: Bigstock
IQVIA Gears Up to Report Q3 Earnings: Here's What You Should Know
IQVIA Holdings, Inc. (IQV - Free Report) is scheduled to release its third-quarter 2024 results on Oct. 31, before market open.
See Zacks Earnings Calendar to stay ahead of market-making news.
IQVIA Holdings Inc. Price and EPS Surprise
IQVIA Holdings Inc. price-eps-surprise | IQVIA Holdings Inc. Quote
IQV has an impressive earnings surprise history, having surpassed the Zacks Consensus Estimate in the trailing four quarters, the average surprise being 1.8%.
IQVIA’s Q3 Expectations
The Zacks Consensus Estimate for revenues is pegged at $3.9 billion, implying 3.1% growth from the year-ago quarter’s actual. The top line is likely to have been driven by increased revenues across the Technology and Analytics segment (TAS), and Research and Development segments (RD&S).
Our estimate for revenues from TAS is pegged at $1.5 billion, suggesting a 4.9% gain on a year-over-year basis. This segment’s revenue growth is expected to be fueled by improvements in Consulting and Analytics. The launch of a GenAI solution, which collects structured and unstructured survey inputs from more than 30,000 healthcare professionals across 36 countries in multiple languages and delivers analytics and insights to its clients, is likely to have benefited this segment.
The RD&S revenues are expected to be $2.2 billion, hinting at a 2.4% rise from the year-ago reported figure.Revenues in this segment are anticipated to be driven by the strength across VRSK’s oncology department.
Our estimate for Contract sales and Medical solutions’ (CSMS) revenues is pegged at $182.9 million, implying a marginal decline from the year-ago quarter’s actual.
The consensus estimate for earnings per share is pegged at $2.8, suggesting 12.9% year-over-year growth. The bottom line is expected to have been driven by revenue growth and cost management discipline.
Our estimate for the third quarter’s adjusted EBITDA is pegged at $938.6 million, suggesting 5.7% year-over-year growth.
What Our Model Says About IQV
Our proven model does not conclusively predict an earnings beat for IQVIA this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here. You can uncover the best stocks before they are reported with our Earnings ESP Filter.
IQV has an Earnings ESP of -0.54% and a Zacks Rank of 3 at present.
Stocks to Consider
Here are a few stocks from the broader Business Services sector, which, according to our model, have the right combination of elements to beat on earnings this time around.
Mastercard (MA - Free Report) : The Zacks Consensus Estimate for the company’s third-quarter 2024 revenues is pegged at $7.3 billion, suggesting growth of 11% from the year-ago quarter. For earnings, the consensus mark is pegged at $3.7 per share, indicating a 10% year-over-year rise. MA beat the consensus estimate in the past four quarters. It has an earnings surprise of 3.5%, on average.
MA has an Earnings ESP of +0.44% and a Zacks Rank of 2 at present. It is scheduled to declare its third-quarter 2024 results on Oct. 30.
You can see the complete list of today’s Zacks #1 Rank stocks here.
Visa (V - Free Report) : The Zacks Consensus Estimate for third-quarter 2024 revenues is pegged at $9.5 billion, indicating an increase of 10.2% from the year-ago quarter’s actual. For earnings, the consensus mark is pegged at $2.6 per share, indicating a 10.7% increase from the year-ago quarter’s actual. V beat the consensus estimate in the past four quarters, the earnings surprise being 2.9%, on average.
V has an Earnings ESP of +0.05% and a Zacks Rank of 3 at present. It is scheduled to declare its third-quarter 2024 results on Oct. 29.